Evidence
Explor Target Antitumor Ther. 2023;4(4):556-568. doi: 10.37349/etat.2023.00152. Epub 2023 Aug 24.
ABSTRACT
Hepatocellular carcinoma (HCC) constitutes an extremely malignant form of primary liver cancer. Intricate connections linking to the immune system might be associated with the pathogenesis of HCC. Meanwhile, immunotherapy with immune checkpoint inhibitors has been established to be a favorable therapeutic possibility for advanced HCC. Although curative opportunities for advanced HCC are restricted, the immune checkpoint immunotherapy has developed as the main choice for treating HCC. However, patients with metabolic-associated fatty liver disease (MAFLD)-linked HCC might be less likely to benefit from the immunotherapy alone. The limitation of the effect of the immunotherapy might be owing to the impaired T cell activation in MAFLD patients, which could be well explained by a dysfunctional gut-liver axis. Gut microbiota and their metabolites including several bile acids could contribute to modulating the responses of the immune checkpoint immunotherapy. Roles of gut microbiota in the development of cancers have expected great interest in the latest studies. Here, an interplay between the gut and liver has been presented, which might suggest to affect the efficacy of immune checkpoint immunotherapy against HCC.
PMID:37720344 | PMC:PMC10501893 | DOI:10.37349/etat.2023.00152
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
🌐 90 Days
VR Related Evidence Matrix
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma
- Insulin Use and The Risk of Hepatocellular Carcinoma: Insights and Implications
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- Integrating single-cell and bulk sequencing data to identify glycosylation-based genes in non-alcoholic fatty liver disease-associated hepatocellular carcinoma
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes
- Clinical outcomes of hepatocellular carcinoma surveillance in Melbourne, Australia
- Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy
- Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy
- Radionuclide Therapy With 177Lu-PSMA in a Patient With Hepatocellular Carcinoma
- Potential Role of MAP3K14 in Hepatocellular Carcinoma: A Study Based on Comprehensive Bioinformatical Analysis and Validation
- Potential Role of MAP3K14 in Hepatocellular Carcinoma: A Study Based on Comprehensive Bioinformatical Analysis and Validation
- Epigenetic regulation of hepatocellular carcinoma progression: microRNAs as therapeutic, diagnostic and prognostic factors
- Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma
- Transcription Factor MAZ Potentiates the Upregulated NEIL3-mediated Aerobic Glycolysis, Thereby Promoting Angiogenesis in Hepatocellular Carcinoma
- Intestinal Barrier Dysfunction and Gut Microbiota in Non-Alcoholic Fatty Liver Disease: Assessment, Mechanisms, and Therapeutic Considerations
- Comparative outcomes of trans-arterial radioembolization in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease-induced HCC: a retrospective analysis
- Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD)
- Cyclophilin D knockout significantly prevents HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH
- Nanoquercetin and Extracellular Vesicles as Potential Anticancer Therapeutics in Hepatocellular Carcinoma
- Identification of differentially expressed mRNA/lncRNA modules in acutely regorafenib-treated sorafenib-resistant Huh7 hepatocellular carcinoma cells
- The involvement of ROS-regulated programmed cell death in hepatocellular carcinoma
- Transplant and non-transplant HCC patients at a single institution
- Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
- Role of prostaglandin E2 and its receptors in chronic liver disease
- Hepatocellular Carcinoma in Ceará: Epidemiology and Treatment in a Reference Liver Transplant Center in Northeast Brazil
- Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients
- Changes in the etiology of liver cirrhosis and the corresponding management strategies
- Postoperative Lenvatinib plus PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with MVI (BCLC 0-A): A Propensity Score Matching Analysis
- A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action
- Prognostic analysis of sex and age in hepatocellular carcinoma: a SEER study
- Role of the angiopoietin-like protein family in the progression of NAFLD
- Association between sex and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis
- A model of alcoholic liver disease based on different hepatotoxics leading to liver cancer
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- Liver Transplantation in Chronic Liver Disease and Acute on Chronic Liver Failure- Indication, Timing and Practices
- The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review
- Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity
- Nephrological Detrimental Impacts Resulting From Novel Immunotherapy Drugs Used in the Treatment of Cancer: A Systematic Review
- Microsatellite Instability, Mismatch Repair, and Tumor Mutation Burden in Lung Cancer
- Impact of the diagnosis of metabolic dysfunction-associated fatty liver disease and non-alcoholic fatty liver disease in patients undergoing liver transplantation for hepatocellular carcinoma
- Recent advances in lung cancer research: unravelling the future of treatment
- Probiotics-A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases
- Gut microbiota induced epigenetic modifications in the non-alcoholic fatty liver disease pathogenesis
- Research progress in the regulation of pathogenesis and the transformation of chronic liver disease by short-chain fatty acids
- Alcohol use disorders and liver fibrosis: an update
- Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors
- Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report
- Dysbiosis in Multiple Sclerosis: Can Immunoglobulin Y Supplements Help?
- Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application
- Unveiling spatial complexity in solid tumor immune microenvironments through multiplexed imaging
- ZNF692 promotes the migration and response to immunotherapy of clear cell renal cell carcinoma cells by targeting metabolic pathway
- The relationship between advanced liver fibrosis and osteoporosis in type 2 diabetes patients with MAFLD
- The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance
- Inflammatory liver diseases and susceptibility to sepsis
- White Adipose Tissue in Metabolic Associated Fatty Liver Disease
- Emerging measurements for tumor-infiltrating lymphocytes in breast cancer
- Targeting metabolic-associated fatty liver disease in diabetic kidney disease: A call to action
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Crosstalk in extrahepatic and hepatic system in NAFLD/NASH
- Interpretable machine learning-based individual analysis of acute kidney injury in immune checkpoint inhibitor therapy
Evidence Blueprint
Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
🌐 365 Days
VR Related Evidence Matrix
- Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options
- An overview of mouse models of hepatocellular carcinoma
- Gamma Delta T Cells: Role in Immunotherapy of Hepatocellular Carcinoma
- The effect of liver disease on hepatic microenvironment and implications for immune therapy
- METTL3 drives NAFLD-related hepatocellular carcinoma and is a therapeutic target for boosting immunotherapy
- Real-World Use of Immunotherapy for Hepatocellular Carcinoma
- Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players
- Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma
- Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology
- Three-Dimensional Structure of Novel Liver Cancer Biomarker Liver Cancer-Specific Serine Protease Inhibitor Kazal (LC-SPIK) and Its Performance in Clinical Diagnosis of Hepatocellular Carcinoma (HCC)
- Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma
- Recent advances in the management of hepatocellular carcinoma
- Metabolic dysfunction-associated fatty liver disease and the risk of hepatocellular carcinoma
- Regulation of Hepatocellular Carcinoma Epithelial-Mesenchymal Transition Mechanism and Targeted Therapeutic Approaches
- New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma-Today and Tomorrow
- The rs72613567:TA polymorphism in HSD17B13 is associated with survival benefit after development of hepatocellular carcinoma
- Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis
- Alternative splicing: a bridge connecting NAFLD and HCC
- Non-alcoholic fatty liver disease-related hepatocellular carcinoma
- Roles of peroxisome proliferator-activated receptors in hepatocellular carcinoma
- Phytochemicals as Potential Lead Molecules against Hepatocellular Carcinoma
- Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma
- Insulin Use and The Risk of Hepatocellular Carcinoma: Insights and Implications
- Challenges and Solutions in the Management of Hepatocellular Carcinoma Associated with Non-Alcoholic Fatty Liver Disease
- Loss of cis-PTase function in the liver promotes a highly penetrant form of fatty liver disease that rapidly transitions to hepatocellular carcinoma
- Berberine prevents NAFLD and HCC by modulating metabolic disorders
- Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B
- Pan-Cancer Profiling and Digital Pathology Analysis Reveal Negative Prognostic Biomarker ZPR1 Associated with Immune Infiltration and Treatment Response in Hepatocellular Carcinoma
- Patients undergoing liver resection for non-alcoholic fatty liver disease-related hepatocellular carcinoma and those for viral hepatitis-related hepatocellular carcinoma have similar survival outcomes
- The Current Landscape of Therapies for Hepatocellular Carcinoma
- Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters?
- Tumour stemness and poor clinical outcomes in haemochromatosis patients with hepatocellular carcinoma
- Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States
- A Rare Type of Hepatocellular Carcinoma Presenting With Cardiac Thrombus
- Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma
- N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas
- Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis
- Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma
- Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)
- Integrating single-cell and bulk sequencing data to identify glycosylation-based genes in non-alcoholic fatty liver disease-associated hepatocellular carcinoma
- Identification of differentially methylated regions associated with both liver fibrosis and hepatocellular carcinoma
- Lactobacillus acidophilus suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma through producing valeric acid
- The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
- SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea
- Prognostic and immune roles of UROC1 in human cancers: from mechanism exploration of NAFLD and HCC to pan-cancer analysis
- Tumorigenesis from non-alcoholic steatohepatitis to hepatocellular carcinoma
- Non-alcoholic fatty liver disease and diabetes mellitus as growing aetiologies of hepatocellular carcinoma
- Comparison between models for detecting hepatocellular carcinoma in patients with chronic liver diseases of various etiologies: ASAP score versus GALAD score
- Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: the Multi-center Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study
- Chest wall mass as a sign of ignored hepatocellular carcinoma in an alcoholic cirrhotic patient: a case report
- A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD
- Small-interfering RNA targeting proprotein convertase subtilisin/kexin type 9 might promote fatty liver disease and hepatocellular carcinoma through upregulation of CD36
- Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma
- Values of ATX in predicting disease progression in patients with PBC and PBC related HCC
- Analysis of genetic factors associated with fatty liver disease-related hepatocellular carcinoma
- Distinct Morphological and Molecular Profiles of NAFLD and NAFLD-associated HCC Revealed by Immunohistochemistry and MicroRNA Analysis
- A Review of Incidence and Related Risk Factors in the Development of Hepatocellular Carcinoma
- Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes
- Inhibition of IL-33 signaling ameliorate hepatic fibrosis with decreasing MCP-1 in a mouse model of diabetes and non-alcoholic steatohepatitis; comparison for luseogliflozin, an SGLT2 inhibitor
- The Impact of Probiotic Bifidobacterium on Liver Diseases and the Microbiota
- Improved Survival in At-Risk Patients Undergoing Surveillance for Hepatocellular Carcinoma - A Nationwide Swedish Register-Based Study
- Alcohol use and hepatocellular carcinoma risk in patients with alcohol-related cirrhosis
- Past, present, and future of chemically induced hepatocarcinogenesis rodent models: Perspectives concerning classic and new cancer hallmarks